

7 November 2006



Mr Christopher Feinmann
Technology Appraisal Project Manager
The National Institute for Health and
Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA

*Quarry House
Quarry Hill
Leeds
LS2 7UE*

Dear Christopher

**Single Technology Appraisal: Fludarabine for the
treatment of lymphocytic leukaemia – Appraisal
Consultation Document**

Thank you for inviting the Department of Health to comment on NICE's Appraisal Consultation Document on Fludarabine, for the treatment of lymphocytic leukaemia.

The Department has no substantive comments to make, though colleagues noted that the key trial in the Fludarabine appraisal has limited follow-up, with no known survival difference, and very limited quality of life data. This is presumably reflected in the wide range of cost effectiveness estimates.

Yours sincerely